linjc16/ctgov huggingface dataset:
Trial in Cardiac Resynchronization Therapy (CRT): Right Ventricular Apex Versus High Posterior Septum

Study Overview
=================
Brief Summary
-----------------
In heart failure patients we hypothesised that right ventricular high posterior septum is superior to right ventricular apex in CRT and DDD pacemaker. In two separate trials we prospectively randomized the right ventricular lead placement to find evidence of differences in heart failure symptoms (NYHA-class), 6 minute hall walk and echocardiographic measurements of reverse remodelling and dyssynchrony.

Official Title
-----------------
Echocardiographic Dyssynchrony in Heart Failure in CRT; Right Ventricular Apex v.s. High Posterior Septum

Conditions
-----------------
Heart Failure

Intervention / Treatment
-----------------
* Device: CRT in heart failure; Right ventricular apex v.s. high posterior septum
* Device: CRT in heart failure; Right ventricular apex v.s. high posterior septum


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CRT: LVEF < 35% LVEDD > 5.5 cm NYHA 3-4 QRS > 120 ms Optimal medical treatment Both CRT-pacemakers (CRT-P) and CRT combined with ICD (CRT-D) Exclusion Criteria: Not fulfilling inclusion criteria or not written consensus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: CRT; RV apical lead placement<br>Right ventricular apical lead placement in CRT | Device: CRT in heart failure; Right ventricular apex v.s. high posterior septum<br>* RV lead is randomized to either apex or high posterior septum<br>|
| Active Comparator: CRT; RV high posterior septum<br>High posterior septal lead placement in CRT | Device: CRT in heart failure; Right ventricular apex v.s. high posterior septum<br>* RV lead is randomized to either apex or high posterior septum<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Echocardiographic reverse remodelling and dyssynchrony |  | 3, 6, 12, 18 and 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pacemaker treatment in heart failure, Cardiac resynchronization therapy, DDD pacemakers
Conditioning Regimen Before Infusion of Allogeneic Hematopoietic Stem Cells

Study Overview
=================
Brief Summary
-----------------
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients with Hematologic Malignancies.

Detailed Description
-----------------
Primary end points are treatment-related mortality and engraftment. Secondary end points are regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival.

Official Title
-----------------
Unrelated Donor Hematopoietic Stem Cell Transplantation After Nonmyeloablative Conditioning for Younger Patients With Hematologic Malignancies

Conditions
-----------------
HEMATOLOGIC MALIGNANCIES

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: -Patients should have an unrelated donor who is matched for HLA-A and -B by serology and for -DRB1 by molecular typing. Exclusion Criteria: Patients should not have major illness or organ failure Patients must not have a psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike, and making informed consent impossible. Patients must not be pregnant or lactating.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| treatment-related mortality and engraftment |  | all cause mortality | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| regimen-related toxicities, graft-versus-host-disease, relapse, and overall survival. |  | Time point(s) at which outcome measure is assessed. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patients without comorbidity
ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging (Adodream)

Study Overview
=================
Brief Summary
-----------------
To date, no MRI study has been published describing the prevalence of endometriosis in adolescent girls, not even in those with significant dysmenorrhea and therefore more particularly at risk. Likewise, there are no precise data on the type of superficial or early-onset deep endometriosis that appears in adolescence. The collection of these data would allow an earlier diagnosis, because it is better documented, of endometriosis. The lesions would then be treated earlier, avoiding their development and the problems of infertility related to this pathology. The aim of this sudy is to assess the prevalence of endometriosis and its phenotypic representation in the study population consulting for dysmenorrhea with suspected endometriosis.

Official Title
-----------------
ADOlescent DysmenoRrhea Endometriosis Assessment Magnetic Resonance Imaging

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Procedure: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged between 12 and 20 years old. After menarche. Requiring pelvic MRI for exploration of dysmenorrhea (after or not ultrasound), in the case of patients with suspected endometriosis, or for any other reason (cyst, tumor, non-obstructive urogenital malformations), in the case of patients without symptoms clinic associated with endometriosis. Patient affiliated or beneficiary of a social security scheme. Patient and her legal representative, if applicable, having been informed and not opposing this research. Exclusion Criteria: Patient whose pelvic MRI is performed as part of an exploration of obstructive uterine malformations. Patient claustrophobic, making it impossible to perform an MRI. Contraindication to MRI: pacemaker, ferromagnetic object incompatible with MRI. Pregnant, breastfeeding or parturient woman. Protected patient: Major under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision; Hospitalized without consent.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: MRI|Pelvic MRI without injection of contrast product and WITHOUT rectal or vaginal opacification|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patient with endometriosis detected on MRI |  | 1 day |
Blood Loss and Preeclampsia

Study Overview
=================
Brief Summary
-----------------
Study of blood loss in preeclamptic patients using mathematical formulae

Detailed Description
-----------------
Pre-eclampsia is a symptom complex that occurs in 2-5% of all pregnancies and leads to significant morbidity and mortality. It is associated with a risk of impaired coagulation caused by a reduced platelet count, very rarely by disseminated intravascular coagulation disorders. The degree of clotting correlates with the severity of preeclampsia. It is planned to calculate the blood loss using mathematical formulas and to compare the different blood loss in the two groups (preeclampsia vs. healthy pregnant women). Furthermore, this project will try to correlate the blood loss with the underlying coagulation situation. The aim is to be able to better assess the bleeding risk in healthy pregnant women, but also in pre-eclamptic patients in the future.

Official Title
-----------------
Does Preeclampsia Affect Blood Loss During a Caesarean Procedure

Conditions
-----------------
Pre-Eclampsia; Complicating Pregnancy, Blood Loss, Coagulation Disorder

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective or urgent caesarean section Written informed consent Exclusion Criteria: Emergency caesarean section Familial coagulation disorder Hematological disorders that affect the platelet count, e.g. myelodysplastic syndrome (MDS) Taking anticoagulants Taking aspirin in the last 14 days Use of NSARs in the last 24 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| healthy pregnant women<br>Healthy patients who receive a cesarean operation | Other: Blood sample<br>* Two blood sample will be drawn. On the day of operation and the first postoperative day.<br>|
| Pre-eclampsia<br>Patients with pre-eclampsia who receive a caesarean operation | Other: Blood sample<br>* Two blood sample will be drawn. On the day of operation and the first postoperative day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood-Loss | Corelation between blood loss and coagulation parameters will be calculated | day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Coagulation parameter | Impact of pre-eclampsia on the coagulation parameters | day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pre-eclampsia, blood-loss, impaired coagulation
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.

Detailed Description
-----------------
The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.

Official Title
-----------------
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients (Old Title: Significance of CD44 and or Epithelial Specific Antigen Positive Cells in the Peripheral Blood of Lung Cancer Patients) (LUN0017)

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Procedure: phlebotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases): Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection ability to sign informed consent at least 18 years of age Inclusion Criteria (Controls): no known prior or active malignancy ability to sign informed consent at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years 2. pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: phlebotomy|Standard of care|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells. |  | 2 years |
The Role of Inflammation in Ocular Tumours

Study Overview
=================
Brief Summary
-----------------
This prospective, non-therapeutic study will determine whether a novel imaging technique can identify presumptive tumour associated macrophages (TAMs) in patients with ocular tumours. The investigators will evaluate 5 groups: Choroidal nevus Choroidal indeterminate melanocytic lesion Choroidal melanoma Suspected metastatic tumour (ie, primary tumour elsewhere) Locally treated ocular tumours

Official Title
-----------------
The Role of Inflammation in Ocular Tumours

Conditions
-----------------
Ocular Melanoma

Intervention / Treatment
-----------------
* Other: cSLO imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any tentative clinical diagnosis of: Choroidal nevus (low-risk features): Choroidal indeterminate melanocytic lesion (high-risk features) Choroidal melanoma Suspected metastatic tumour (ie, primary tumour elsewhere) Locally treated ocular tumours Note that a patient can enroll in this study twice, once before treatment and once after, provided that at least one month has passed since initiation of treatment. This patient will count twice (ie, once in each of two study arms) Male and female age 18 years and older Ability to provide informed consent Exclusion Criteria: Allergy to angiography dye Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study. Patients not able to provide consent for the study. Patients with a poor view of the fundus due to cataract or vitreous hemorrhage. Patients < 18 years of age. Any concurrent unrelated eye diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Choroidal nevus<br>Requires distinction from melanoma through diagnostic testing (low-risk features) | Other: cSLO imaging<br> <br> |
| Choroidal indeterminate melanocytic lesion<br>Requires diagnostic testing for identification and distinction from nevus and melanoma (high-risk features) | Other: cSLO imaging<br> <br> |
| Choroidal melanoma<br>Requires confirmation of diagnosis and evaluation for potential metatstases | Other: cSLO imaging<br> <br> |
| Suspected metastatic tumour<br>Requires identification of primary tumour (ie, primary tumour elsewhere) | Other: cSLO imaging<br> <br> |
| Locally treated ocular tumour<br>Requires followup to evaluate response to treatment and potential change or repeat therapy | Other: cSLO imaging<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of macrophages |  | 1 week |
Opinions of Company Representatives About Neuromodulation

Study Overview
=================
Brief Summary
-----------------
The goal of this online survey is to gain further insight in the goals, expectations and definition of success for neuromodulation for pain, according to neuromodulation company representatives.

Official Title
-----------------
Opinions of Company Representatives About Neuromodulation for Pain: an Online Survey

Conditions
-----------------
Neuromodulation, Pain, Survey

Intervention / Treatment
-----------------
* Behavioral: Filling in an online survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Male and female adults who are involved in the management of chronic pain and more specifically in neuromodulation for pain as company representatives will be eligible to complete the survey. Exclusion Criteria: - Not a company representative.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Company representatives<br> | Behavioral: Filling in an online survey<br>* Company representatives are questioned about three aspects: 1) goals in treating patients with neuromodulation for pain, 2) factors that respondents expect to change according to neuromodulation for pain and 3) their definition of success of neuromodulation for pain.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Goals of company representatives, evaluated with a self-constructed question. | Goals of company representatives to treat patients with neuromodulation for pain. | Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September. | 
| Company representatives expectations, evaluated with a self-constructed question. | Factors that respondents expect to change according to neuromodulation for pain. | Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September. | 
| Company representatives definition of success of neuromodulation for pain, evaluated with a self-constructed question. | Company representatives their definition of success of neuromodulation for pain. | Cross-sectional evaluation during 2nd Joint Congress of the INS European Chapters (e-INS 2021) in Paris in September. |
Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the incidence and clinical history of neurofibromatosis type 1-related spinal abnormalities.

Detailed Description
-----------------
Neurofibromatosis type 1 (NF1) is a common genetic disorder that is associated with spinal abnormalities which are varied and may include scoliosis, neurofibromas, meningoceles, and vertebral defects. Skeletal abnormalities occur in more than one third of individuals with the disorder. These abnormalities are unpredictable and the pathogenesis, natural history, and clinical outcome remain relatively unclear. The primary objective of this study is to determine the incidence and clinical history of NF1-related spinal abnormalities in children with NF1, over a 3-year period. In the study, researchers will enroll children between ages 6 and 9 years who have been diagnosed with NF1 to look at changes in the spine. Participants in the study will be followed yearly for a total of 4 evaluations. Evaluations may include bone scans, spinal x-rays, magnetic resonance imaging (MRI), computed tomography (CT) scans, and urine samples. Information gained from this study may lead to a better understanding of the causes of bone disease in NF1, and improved treatment.

Official Title
-----------------
Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)

Conditions
-----------------
Neurofibromatosis Type 1

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of NF1 Age greater than 6 years at time of enrollment Age less than 9 year and 1 day at time of enrollment Tanner Stage not greater than 1 Exclusion Criteria: Prior surgical repair of spine Short-segment (4-6 vertebrae) curve with a Cobb angle of 45°or more Hormone replacement therapy Chronic steroid use Tibial pseudarthrosis Other chronic medical problems known to influence bone health (i.e. diabetes mellitus, cerebral palsy, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Neurofibromatosis Type 1<br>Children with Neurofibromatosis Type 1 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scoliosis and it's progression |  | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differences in other bone health variables as measured by thoracic MRIs, Dexa (xray measuring bone density), pQCT (a cross sectional picture of the tibia), urine analysis, and scoli series (xrays to look for scoliosis). |  | 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neurofibromatosis type 1, spinal abnormalities, scoliosis